Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2007

01-10-2007 | Review

Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature

Authors: Alessandro M. Minisini, Giada Pauletto, Paolo Bergonzi, Gianpiero Fasola

Published in: Breast Cancer Research and Treatment | Issue 2/2007

Login to get access

Abstract

Paraneoplastic neurological syndromes are a rare complication of breast cancer. Nevertheless, they may be clinically relevant leading to neurological impairment. Clinicians should be aware that these neurological disorders could even precede the diagnosis of breast cancer. Here we present the case of a female patient with advanced breast cancer who developed paraneoplastic sensorimotor neuropathy. Treatment with capecitabine lead to clinical amelioration. A review of the literature on the paraneoplastic neurological syndromes in breast cancer is also included.
Literature
1.
Dalmau J, Gultekin HS, Posnes JB (1999) Paraneoplastic neurological syndromes: pathogenesis and physiopathology. Brain Pathol 9:261–273
2.
3.
Cao Y, Abbas J, Wu X, Dooley J et al (1999) Anti-Yo positive paraneoplastic cerebellar degeneration associated with ovarian carcinoma: case report and review of the literature. Gynecol Oncol 75:178–183PubMedCrossRef
4.
Peltola J, Hietaharju A, Rantala I et al (1998) A reversible neuronal antibody (anti-Tr) associated paraneoplastic cerebellar degeneration in Hodgkin’s disease. Acta Neurol Scand 98:360–363PubMedCrossRef
5.
Ohguro H, Yokoi Y, Ohguro I et al (2004) Clinical and immunologic aspects of cancer-associated retinopathy. Am J Ophthalmol 137:1117–1119PubMedCrossRef
6.
Newsom-Davis J (2004) Lambert-Eaton myasthenic syndrome. Rev Neurol (Paris) 160:177–180
7.
Tomimitsu H, Arimura K, Nagado et al (2004) Mechanism of action of voltage-gated K+ channel antibodies in acquired neuromyotonia. Ann Neurol 56:440–444PubMedCrossRef
8.
Altaha R, Abraham J (2003) Paraneoplastic neurological syndrome associated with occult breast cancer: a case report and review of literature. Breast J 9:417–419PubMedCrossRef
9.
Rojas-Marcos I, Rousseau A, Keime-Guibert F et al (2003) Spectrum of paraneoplastic neurological disorders in women with breast and gynaecologic cancer. Medicine (Baltimore) 82:216–223CrossRef
10.
Peterson K, Rosenblum MK, Kotanides H et al (1992) Paraneoplastic cerebellar degeneration. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 42:1931–1937PubMed
11.
Gatti G, Sismek S, Kurne A et al (2003) Paraneoplastic neurological disorders in breast cancer. Breast 12:203–207PubMedCrossRef
12.
Budde-Steffen C, Anderson NE, Rosenblum MK et al (1988) An antineuronal autoantibody in paraneoplastic opsoclonus. Ann Neurol 23:528PubMedCrossRef
13.
Poser JB (1995) Paraneoplastic syndromes. In:Poser JB (ed) Neurological complication of cancer. Contemporary neurology series 45, OUP, New York
14.
Ohguro H, Nakazawa M (2002) Pathological roles of recoverin in cancer-associated retinopathy. Adv Exp Med Biol 514:109–124PubMed
15.
Chan C, O’Day J (2001) Melanoma-associated retinopathy: does autoimmunity prolong survival? Clin Experiment Ophthalmol 29:235–138PubMedCrossRef
16.
Folli F, Piccolo G (2002) Stiff-man syndrome: pathogenetic, nosological, and therapeutic considerations. In:Vincent A, Martino G (ed) Antibodies in neurological disease, 1st edn. Springer-Verlag, Italia, Milano
17.
Pringle CE, Hudson AJ, Munoz DG et al (1992) Primary lateral sclerosis. Clinical features, neuropathology and diagnostic criteria. Brain 115:495–520PubMedCrossRef
18.
Corcia P, Honnorat J, Guennoc AM et al (2000). Primary lateral sclerosis with breast cancer, a potential paraneoplastic neurological syndrome. Rev Neurol (Paris) 156:1020–1022
19.
Wakata N, Kurihara T, Saito E, Kinoshita M (2002) Polymyositis and dermatomyositis associated with malignancy: a 30 years retrospective study. Int J Dermatol 41:729–734PubMedCrossRef
20.
Levin MI, Mozaffar T, Al-Lozi MT et al (1998) Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 50:764–767PubMed
21.
Rudnicki SA, Dalmau J (2005) Paraneoplastic syndromes of the peripheral nerves. Curr Opin Neurol 18:598–603PubMedCrossRef
22.
Camdessanche JP, Antoine JC, Honnorat J et al (2002) Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain 125:166–175 PubMedCrossRef
23.
Quarles RH, Weiss MD (1999) Autoantibodies associated with peripheral neuropathy. Muscle Nerve 22:800–822PubMedCrossRef
24.
Graus F, Delattre JY, Antoine JC et al (2004) Recommended diagnostic criteria for paraneoplastic neurologicl syndromes. J Neuro Neurosurg Psychiatr 75:1135–1140CrossRef
25.
Metadata
Title
Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature
Authors
Alessandro M. Minisini
Giada Pauletto
Paolo Bergonzi
Gianpiero Fasola
Publication date
01-10-2007
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9444-0

Other articles of this Issue 2/2007

Breast Cancer Research and Treatment 2/2007 Go to the issue

Original paper

Risk for contralateral breast cancers in a population covered by mammography: effects of family history, age at diagnosis and histology

Epidemiology

Psychometric properties of the simplified Chinese version of the EORTC QLQ-BR53 for measuring quality of life for breast cancer patients

Preclinical Study

Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma

Epidemiology

Weight gain and recovery of pre-cancer weight after breast cancer treatments: evidence from the women’s healthy eating and living (WHEL) study

Research Paper

Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers

Epidemiology

Psychological distress and fatigue predicted recurrence and survival in primary breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits